Cancer Biologics Market size is set to grow by USD 51.08 billion from 2024-2028, Rising global incidence of cancer boost the market, Technavio

NEW YORK, May 30, 2024 /PRNewswire/ -- The global cancer biologics market  size is estimated to grow by USD 51.08 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  9.18%  during the forecast period. 

For more insights on the forecast market size and historic data (2017 - 2020) - Download a Sample Report

Segment Overview 

1. Product 
• 1.1 Monoclonal antibodies
• 1.2 Cell and gene therapy
• 1.3 Vaccines
• 1.4 Others
2. Route Of Administration 
• 2.1 Injectable
• 2.2 Oral
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 Monoclonal antibodies-  Monoclonal antibodies play a significant role in cancer treatment through targeted therapy and immunotherapy. These antibodies inhibit tumor growth by acting on specific targets, primarily cascade proteins involved in angiogenesis. Minimal side-effects make monoclonal antibodies highly sought-after for various cancer types. Approved monoclonal antibodies include Herceptin, Avastin, and others. New drug approvals and a large pipeline contribute to the market's growth, with monoclonal antibodies leading the cancer biologics sector.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

Market Driver

The cancer biologics market is witnessing an increase in strategic collaborations among manufacturers. In 2021, Curia acquired LakePharma Inc., a US-based CRDMO, to expand its capabilities in biologics discovery and manufacturing. In 2020, Cytovance Biologics collaborated with Akshaya Bio to provide quick access to clinical materials using Akshaya's technology. In 2019, Bristol-Myers Squibb acquired Celgene for USD74,000 million to broaden their offerings for cancer patients. These collaborations and acquisitions will boost the growth of the cancer biologics market. 

The Cancer Biologics Market is experiencing significant growth due to the increasing demand for innovative treatments. Biologics, such as monoclonal antibodies and cell therapies, are becoming key players in cancer treatment. Companies are investing in research and development to bring new products to market. For instance, there is a focus on developing targeted therapies and immunotherapies.

Additionally, there is a trend towards personalized medicine, which involves tailoring treatments to individual patients based on their genetic makeup. Vaccines and gene therapies are also gaining attention in the cancer biologics market. Overall, the market is expected to continue growing as new treatments are discovered and approved. 

Market Challenges

• The cancer biologics market is characterized by high costs due to advanced production processes and regulatory requirements. Monoclonal antibodies, such as KEYTRUDA and TECENTRIQ, have expensive production procedures and skilled personnel needs, leading to high prices.
• Gene therapies, like KYMRIAH, require individualized design and advanced procedures, further increasing costs. These high prices limit affordability and availability, particularly in low and middle-income countries. Reimbursement is a challenge due to the cost of mandatory companion diagnostics and insurers' preference for biosimilars over biologics.
• The Cancer Biologics Market faces several challenges in the adoption and implementation of various therapies. These include the high cost of advanced cell technologies, regulatory hurdles, and the need for personalized treatment plans. Additionally, the complexity of cancer biology and the diversity of cancer types pose significant challenges in developing effective therapies.
• Furthermore, the lack of standardized testing methods and the need for long-term clinical trials add to the difficulties. Despite these challenges, the market continues to grow due to the potential of these therapies to offer more targeted and effective treatments for cancer patients.

Research report provides comprehensive data on impact of trend, driver and challenges - Request a sample report!

Research Analysis

The Cancer Biologics Market encompasses a range of innovative treatments derived from living organisms, including animals, humans, and microorganisms. Biotechnology plays a pivotal role in the production of these therapies, which include Blood-derived components, such as vaccines and immunoconjugates, as well as Cell-based therapies, like Adoptive cell transfer and Cytokine therapy.

Genetic material, specifically Genes, is utilized in Gene therapy and Monoclonal antibodies. In the realm of Oncology, various approaches are employed, including Cancer vaccines, Oncolytic virus therapy, and Targeted drug therapy. Clinical trials are essential for the development and approval of these advanced treatments.

Market Research Overview

The Cancer Biologics Market refers to the sector focused on developing and commercializing therapeutic products derived from living organisms for the prevention, treatment, and diagnosis of cancer. This market encompasses various types of biologics, including monoclonal antibodies, immunotherapies, gene therapies, and cellular therapies. The market is driven by the increasing prevalence of cancer worldwide, advancements in biotechnology, and growing demand for personalized cancer treatments.

The Alliance for Cancer Gene Therapies, Cells for Cancer Therapy, and the American Society of Gene and Cell Therapy are some organizations contributing to the advancement of cancer biologics. The market is also influenced by regulatory frameworks, reimbursement policies, and technological innovations in the field of cancer research.

The use of vaccines, targeted therapies, and combination therapies are some trends shaping the cancer biologics market. The market is expected to grow significantly in the coming years due to the increasing number of cancer survivors and ongoing research and development efforts.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
• Monoclonal Antibodies
• Cell And Gene Therapy
• Vaccines
• Others
• Route Of Administration
• Injectable
• Oral
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED